Skip to main content
SSY Group Limited logo

SSY Group Limited — Investor Relations & Filings

Ticker · 2005 ISIN · KYG8406X1034 HKEX Manufacturing
Open in API
Filings indexed 1,213 across all filing types
Latest filing 2025-05-30 Earnings Release
Country HK Hong Kong
Listing HKEX 2005

About SSY Group Limited

http://www.ssygroup.com.hk

SSY Group Limited is an investment holding company specializing in the research, development, manufacturing, and sale of pharmaceutical products. The Group is a prominent manufacturer, with a core focus on producing a wide range of intravenous infusion solutions and finished drugs. Complementing its pharmaceutical offerings, the company also manufactures essential packaging materials, including non-PVC soft bags and PP plastic containers. SSY Group supplies its comprehensive product line, which often utilizes green production technologies aimed at reducing costs and power consumption, primarily to hospitals and medical institutions.

Recent filings

Filing Released Lang Actions
(1) UNAUDITED OPERATING RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2025 AND (2) PROFIT WARNING - INTERIM RESULTS FOR THE SIX MONTHS ENDING 30 JUNE 2025
Earnings Release Classification · 85% confidence The document is a market announcement on HKEX that provides unaudited operating results for Q1 2025 and issues a profit warning for H1 2025. It contains key financial highlights (turnover, gross profit, net profit change percentages) and clearly states that these are preliminary unaudited figures, with full interim results to follow. This matches the definition of an Earnings Release (ER): an initial announcement of quarterly/periodical financial results with key highlights only. It is not a full interim report, management discussion & analysis, or regulatory filing announcing report publication. Q1 2025
2025-05-30 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 78% confidence The document is a brief voluntary announcement regarding product development (approval of a generic drug consistency evaluation) by the company’s board. It does not present financial results, governance details, meeting materials, or any specific regulatory form content. It is not an AGM presentation nor an earnings release but rather a general business update. This falls into the fallback category for miscellaneous regulatory announcements that do not fit other filing types.
2025-05-28 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement by SSY Group Limited regarding product development approvals from the National Medical Products Administration (NMPA). It is not a financial report, earnings release, board change, share issuance, or other specific filing type. It is a general corporate announcement provided to keep investors informed, fitting the fallback category for miscellaneous regulatory announcements. Therefore, it should be classified as a Regulatory Filing (RNS).
2025-05-21 English
POLL RESULTS OF ANNUAL GENERAL MEETING 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the poll results from the Annual General Meeting 2025 of SSY Group Limited, detailing vote counts and percentages for each resolution. This fits the definition of “Declaration of Voting Results & Voting Rights Announcements,” which covers official results from shareholder votes at AGMs. Therefore, it should be classified under code DVA.
2025-05-16 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 85% confidence The document is a voluntary corporate announcement about product development (approval of Riluzole) with no financial results, no meeting materials, no voting results, and no detailed report attached. It does not fit any specific category like earnings release, management change, or M&A. It is a general regulatory announcement/fallback type. Therefore, it is classified as a Regulatory Filing (RNS).
2025-05-15 English
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 75% confidence The document is a “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” submitted to the Hong Kong Exchange under Chapter 19B Listing Rules, detailing share capital movements, share option schemes, repurchases and confirmations under Main Board/GEM rules. It is a routine regulatory submission rather than an annual or interim financial report, earnings release, or specific transaction announcement. This falls under the general regulatory filing category.
2025-05-02 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.